Today, at the Dutch Life Science Conference, was announced that PrecorDx is the winner of the Venture Challenge!
We are very proud of our collegue Jaap de Bruin who is co-founder of PrecorDX and Nico van den Berg and Bart Steenma, both researchers at UMC Utrecht. Congrat guys!
For more information contact Jaap de Bruin.
Below the press release:
The winner of the Venture Challenge was announced today at the Dutch Life Sciences Conference. The proud winner of the 2022 spring edition is PrecorDx! The innovative startup PrecorDx has developed a non-invasive diagnostic platform aimed at reducing hospitalization & slowing disease progression in heart failure.
According to the jury, composed of Carine van den Brink, Rob de Ree, Brigitte Drees, Ivan Burkov and Sterre Witteveen, PrecorDx is addressing a real need as experienced by patients suffering from heart failure. They have a clear value proposition on which they can expand in the future. Several studies show that hospitalization can be significantly reduced and disease progression slowed in heart failure patients by monitoring disease progression and adapting medication accordingly. This is currently only possible with an invasive device (CardioMems, Abbott). PrecorDx offers a non-invasive solution to monitor heart failure disease progression. This new diagnostic modality is based on the unique, novel Radio-Frequency Sensing (RFS) technology, which was invented in by Bart Steensma and Nico van den Berg, researchers from the computational imaging group at the UMC Utrecht and patented in 2021. Because of the existing clinical evidence, PrecorDx expects an accelerated time to market by comparing the diagnostic value of RFS directly with its invasive competitor. The PrecorDx team currently consists of Bart Steensma, Nico van den Berg and Jaap de Bruin representing a mix of academic/technical expertise and business expertise. The team has built a strong network of clinical advisors which have confirmed the value proposition for heart failure monitoring. Finally, various follow-on applications have been identified, with total market opportunity potential exceeding >€500M.
‘The Venture Challenge was an incredibly effective experience to accelerate & sharpen our business plan. With PrecorDx, we are on a mission to realize a new diagnostic modality in cardiology. We are very excited to set the next steps in the development of the RF Sensing technology!’ – Jaap de Bruin, co-founder of PrecorDx
The Venture Challenge Fall started in September and today at the Dutch Life Sciences Conference 2022 PrecorDx takes home the €25.000 prize money to invest in their growth. The other highly-motivated participating teams were: Beephonix, NatInLab, D4 Diagnostics and Movax. Contact Jaap de Bruin for more information about PrecorDx.
© Nils van Houts Fotografie